galantamine

(redirected from Razadyne)
Also found in: Dictionary.
Related to Razadyne: Memantine, Reminyl, Exelon

galantamine

 [gah-lan´tah-mēn]
a reversible competitive inhibitor of acetylcholinesterase used as the hydrobromide salt in the treatment of mild to moderate Alzheimer's disease, administered orally.

galantamine

/ga·lan·ta·mine/ (gah-lan´tah-mēn) a reversible competitive inhibitor of acetylcholinesterase used as the hydrobromide salt in the treatment of Alzheimer's disease.

galantamine

(gə-lăn′tə-mēn′)
n.
A drug, C17H21NO3, originally derived from the bulbs of snowdrops and other plants, that inhibits the action of acetylcholinesterase and is used in its hydrobromide form to treat dementia in people with Alzheimer's disease.

galantamine

[gälan′tämēn]
a reversible competitive inhibitor of acetylcholinesterase used as the hydrobromide salt in the treatment of mild to moderate Alzheimer's disease, administered orally.

galantamine

An ACETYLCHOLINESTERASE inhibitor drug used in Alzheimer's disease to increase the amount of ACETYLCHOLINE available for nerve transmission. A brand name is REMINYL.
References in periodicals archive ?
Detailed information on Razadyne / Reminyl including product description, safety and efficacy profiles as well as a SWOT analysis.
Information on the RAZADYNE and RAZADYNE ER patent litigation (which is ongoing) can be found in our filings with the Securities and Exchange Commission ("SEC") in our Annual Report on Form 10-K for the year to December 31, 2008.
Following a decision on August 28, 2008 which rendered the relevant patent invalid, generic versions of RAZADYNE were permitted to enter the US market.
Information on the RAZADYNE patent litigation (which rendered the relevant patent invalid in August 2008) and RAZADYNE ER patent litigation (which is ongoing) can be found in our filings with the SEC in our Annual Report on Form 10-K for the year to December 31, 2007 and in our Quarterly Report on Form 10-Q for the period ended September 30, 2008.
filing an ANDA with the FDA for a generic version of RAZADYNE ER.
In the United States, galantamine is sold as RAZADYNE and RAZADYNE ER by Janssen Pharmaceuticals, Inc.
3TC (lamivudine) (trademarks of GlaxoSmithKline (GSK)) COMBIVIR (lamivudine) (trademark of GSK) DYNEPO (epoetin delta) (trademark of Sanofi Aventis) EPIVIR (lamivudine) (trademark of GSK) EPZICOM (lamivudine) (trademark of GSK) JUVISTA (trademark of Renovo) PENTASA (mesalamine) (trademark of Ferring) RAZADYNE (galantamine) (trademark of Johnson & Johnson) RAZADYNE ER (galantamine) (trademark of Johnson & Johnson) REMINYL (galantamine) (trademark of Johnson & Johnson, excluding UK and Republic of Ireland) REMINYL XL (galantamine) (trademark of Johnson & Johnson, excluding UK and Republic of Ireland) SOLARAZE (diclofenac sodium (3%w/w)) (trademark of Almirall) VANIQA (eflornithine hydrochloride) (trademark of Almirall) ZEFFIX (lamivudine) (trademark of GSK)
marketed as RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide
Includes REMINYL/RAZADYNE and the impact of RAZADYNE ER US launch stocking
Shire/J&J's Razadyne (galantamiune) previously Reminyl and recent entrant a non-AchEI
JUVISTA (trademark of Renovo) PENTASA (trademark of Ferring) RAZADYNE (trademark of Johnson & Johnson) RAZADYNE ER (trademark of Johnson & Johnson) REMINYL (trademark of Johnson & Johnson, excluding UK and Republic of Ireland) REMINYL XL (trademark of Johnson & Johnson, excluding UK and Republic of Ireland) ZEFFIX (trademark of GSK)
Other royalties are primarily in respect of REMINYL and REMINYL ER (known as RAZADYNE and RAZADYNE ER in the US), a product marketed worldwide (excluding the UK and the Republic of Ireland) by Janssen Pharmaceutical N.